Spyridon Fortis

Clinical Associate Professor of Medicine

University of Iowa Hospitals and Clinics

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Spyridon Fortis is a Clinical Associate Professor of Medicine at the University of Iowa Hospitals and Clinics, USA. His research interests focus on systemic inflammation, lung function decline in smokers, and the effects of oxygen supplementation. Through recent publications, he explores associations of ground-glass opacities with systemic inflammation and emphysema progression, as well as the application of spirometry standards in chronic obstructive pulmonary disease.

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (9)

Surya Bhatt

Associate Professor

UNITED STATES

View details

Alejandro Comellas

Professor

Iowa State University

UNITED STATES

View details

Abbie Begnaud

University of Minnesota

UNITED STATES

View details

Arianne K. Baldomero

University of Minnesota

UNITED STATES

View details

Min Hyung Ryu

Assistant Professor

The University of British Columbia

CANADA

View details

Ken Kunisaki

University of Minnesota

UNITED STATES

View details

Karin Hoth

Iowa State University

UNITED STATES

View details

Arie Nakhmani

The University of Alabama

UNITED STATES

View details

Susan Murray

Professor

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Spyridon Fortis

Research Interests

Explore related searches

Contact this professor

About

Articles (20)

Respiratory Exacerbations and Lung Function Decline in People with Smoking History and Normal Spirometry

Reply to Zhang et al.: Assessing the Correlation between Systemic Inflammation and Ground-Glass Opacities: Beyond a Single Indicator

Oxygen Supplementation Goals Beyond Correcting Ambulatory Oxygen Saturation

Longitudinal Outcomes in Pi*MZ Alpha-1 Antitrypsin Deficient Individuals with Tobacco Smoking History from the SPIROMICS Cohort.

Reply to Hatipoğlu et al., Wijkstra et al., and Crimi and Carlucci

Application of the ERS/ATS Spirometry Standards and Race-Neutral Equations in the COPDGene Study

Application of the European Respiratory Society/American Thoracic Society Spirometry Standards and Race-Neutral Equations in the COPDGene Study.

Reply to Hatipoğlu <i>et al.</i> and Wijkstra <i>et al.</i>

Association of Ground-Glass Opacities with Systemic Inflammation and Progression of Emphysema

Association of Ground Glass Opacities with Systemic Inflammation and Progression of Emphysema.

Prevalence of abnormal spirometry in individuals with a smoking history and no known obstructive lung disease.

FEV1/FVC Severity Stages for Chronic Obstructive Pulmonary Disease.

Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD

Predicting severe chronic obstructive pulmonary disease exacerbations using quantitative CT: a retrospective model development and external validation study

Home noninvasive ventilation use in patients hospitalized with COPD.

Changes in Lung Volumes with Spirometric Disease Progression in COPD.

FEV1/FVC Severity Stages for Chronic Obstructive Pulmonary Disease

High versus Medium Dose of Inhaled Corticosteroid in Chronic Obstructive Lung Disease: A Systematic Review and Meta-Analysis

Association of rural living with COPD-related hospitalizations and deaths in US veterans

New Guidelines for Bronchodilator Responsiveness in COPD: A Test in Search of a Use

Collaborators (9)

Surya Bhatt

Alejandro Comellas

Abbie Begnaud

Arianne K. Baldomero

Min Hyung Ryu

Ken Kunisaki

Karin Hoth

Arie Nakhmani

Susan Murray

Make your next move.